141 related articles for article (PubMed ID: 24692689)
1. The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model.
Ramos G; Loperena Y; Ortiz G; Reyes F; Szeto A; Vera J; Velez J; Morales J; Morrero D; Castillo L; Dharmawardhane S; Melendez E; Washington AV
Anticancer Res; 2014 Apr; 34(4):1609-15. PubMed ID: 24692689
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and cytotoxicity studies of steroid-functionalized titanocenes as potential anticancer drugs: sex steroids as potential vectors for titanocenes.
Gao LM; Vera JL; Matta J; Meléndez E
J Biol Inorg Chem; 2010 Aug; 15(6):851-9. PubMed ID: 20349254
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
5. A controlled release system of titanocene dichloride by electrospun fiber and its antitumor activity in vitro.
Chen P; Wu QS; Ding YP; Chu M; Huang ZM; Hu W
Eur J Pharm Biopharm; 2010 Nov; 76(3):413-20. PubMed ID: 20854905
[TBL] [Abstract][Full Text] [Related]
6. New titanocene derivatives with high antiproliferative activity against breast cancer cells.
Saturnino C; Sirignano E; Botta A; Sinicropi MS; Caruso A; Pisano A; Lappano R; Maggiolini M; Longo P
Bioorg Med Chem Lett; 2014 Jan; 24(1):136-40. PubMed ID: 24332626
[TBL] [Abstract][Full Text] [Related]
7. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.
Beckhove P; Oberschmidt O; Hanauske AR; Pampillón C; Schirrmacher V; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):311-5. PubMed ID: 17264764
[TBL] [Abstract][Full Text] [Related]
9. Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer.
Elie BT; Fernández-Gallardo J; Curado N; Cornejo MA; Ramos JW; Contel M
Eur J Med Chem; 2019 Jan; 161():310-322. PubMed ID: 30368130
[TBL] [Abstract][Full Text] [Related]
10. Controlled release of titanocene into the hybrid nanofibrous scaffolds to prevent the proliferation of breast cancer cells.
Laiva AL; Venugopal JR; Karuppuswamy P; Navaneethan B; Gora A; Ramakrishna S
Int J Pharm; 2015 Apr; 483(1-2):115-23. PubMed ID: 25681729
[TBL] [Abstract][Full Text] [Related]
11. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
12. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes.
Pavlaki M; Debeli K; Triantaphyllidou IE; Klouras N; Giannopoulou E; Aletras AJ
J Biol Inorg Chem; 2009 Aug; 14(6):947-57. PubMed ID: 19390879
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice.
Fichtner I; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2006 Mar; 17(3):333-6. PubMed ID: 16520662
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic and DNA-binding Capacity of Titanocene Functionalized Mesoporous Nanoparticles in Breast Cancer Cell Lines MCF-7 and MDA-MB-231.
Serrano-Pindado Á; Iorhemba MA; Díaz-García D; Díaz-Sánchez M; Mena-Palomo I; Gómez-Ruiz S; Prashar S
Curr Pharm Des; 2023; 29(22):1791-1799. PubMed ID: 37518995
[TBL] [Abstract][Full Text] [Related]
15. Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages.
Villena-Heinsen C; Friedrich M; Ertan AK; Schmidt W
Clin Exp Obstet Gynecol; 1998; 25(1-2):5-8. PubMed ID: 9743868
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes.
Chimento A; Saturnino C; Iacopetta D; Mazzotta R; Caruso A; Plutino MR; Mariconda A; Ramunno A; Sinicropi MS; Pezzi V; Longo P
Bioorg Med Chem; 2015 Nov; 23(22):7302-12. PubMed ID: 26526741
[TBL] [Abstract][Full Text] [Related]
17. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
18. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
19. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization and cytotoxic activity on breast cancer cells of new half-titanocene derivatives.
Sirignano E; Saturnino C; Botta A; Sinicropi MS; Caruso A; Pisano A; Lappano R; Maggiolini M; Longo P
Bioorg Med Chem Lett; 2013 Jun; 23(11):3458-62. PubMed ID: 23623493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]